Tinea infection

Summary

Tinea infection (MONDO:0005982) is a disease (an umbrella term covering 9 Mondo subtypes) with 2 GWAS associations across 2 studies and 9 clinical trials. Top therapeutic interventions include isotretinoin, itraconazole, and nitric oxide. A subtype of cutaneous mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 9 Mondo subtypes
• GWAS associations: 2
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tinea infection
Mondo ID	MONDO:0005982
EFO	EFO:0007510
DOID	DOID:12404
NCIT	C112181
UMLS	C0040247
MedGen	52757
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	no

Also known as: ringworm · Tinea · Tinea caused disease or disorder · Tinea disease or disorder · Tinea infection · Tinea infectious disease

Data availability: 2 GWAS associations (2 studies).

Disease family

This is a subtype of cutaneous mycosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › tinea infection

Related subtypes (4): subcutaneous mycosis, dermatomycosis, superficial mycosis, cutaneous basidiobolomycosis

Subtypes (9): otomycosis, conidiobolomycosis, cutaneous candidiasis, dermatophytosis, eumycotic mycetoma, pityriasis versicolor, tinea favosa, deep seated dermatophytosis, fungal infection of the toenail

Genetics & variants

GWAS landscape

2 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs561774588	5e-09	LINC02667 - MGMT	G	7.01

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90018694	Sakaue S	2021	692	178,034	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90018914	Sakaue S	2021	46	354,498	A cross-population atlas of genetic associations for 220 human phenotypes.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs561774588	10	129000451	C>G,T	0.001	intergenic_variant	LINC02667 - MGMT	5e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

12 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ciclopirox	Approved (phase 4)
Clotrimazole	Approved (phase 4)
Efinaconazole	Approved (phase 4)
Griseofulvin	Approved (phase 4)
Itraconazole	Approved (phase 4)
Ketoconazole	Approved (phase 4)
Luliconazole	Approved (phase 4)
Miconazole	Approved (phase 4)
Selenium Sulfide	Approved (phase 4)
Tavaborole	Approved (phase 4)
Terbinafine	Approved (phase 4)
Tolnaftate	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00856596	PHASE3	UNKNOWN	Once a Day Topical Treatment for Athlete’s Foot Fungus Inbetween the Toes in Males and Females
NCT02582177	PHASE3	COMPLETED	Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis
NCT00771342	PHASE2	COMPLETED	Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete’s Foot)
NCT03471455	PHASE2	UNKNOWN	Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis
NCT03823040	PHASE1	COMPLETED	Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel
NCT02759900	Not specified	UNKNOWN	Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
NCT02902822	Not specified	COMPLETED	Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
NCT04265521	Not specified	COMPLETED	Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
NCT07428954	Not specified	COMPLETED	Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ISOTRETINOIN	4	1
ITRACONAZOLE	4	1
NITRIC OXIDE	4	1
NITROGEN	4	1
TERBINAFINE	4	1
HYOSCYAMINE	-1	1